SEC. 307. PEDIATRIC MEDICAL COUNTERMEASURES. 
(a) PEDIATRIC STUDIES OF DRUGS.—Section 505A 
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
355a) is amended— 
(1) in subsection (d), by adding at the end the 
following: 
‘‘(5) CONSULTATION.—With respect to a drug 
that is a qualified countermeasure (as defined in sec-
tion 319F–1 of the Public Health Service Act), a se-
curity countermeasure (as defined in section 319F– 
2 of the Public Health Service Act), or a qualified 
pandemic or epidemic product (as defined in section 
319F–3 of the Public Health Service Act), the Sec-
retary shall solicit input from the Assistant Sec-
retary for Preparedness and Response regarding the 
need for and, from the Director of the Biomedical 
Advanced Research and Development Authority re-
garding the conduct of, pediatric studies under this 
section.’’; and 
(2) in subsection (n)(1), by adding at the end 
the following: 
‘‘(C) For a drug that is a qualified coun-
termeasure (as defined in section 319F–1 of the 
Public Health Service Act), a security counter-
measure (as defined in section 319F–2 of the 
Public Health Service Act), or a qualified pan-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00081
Fmt 6652
Sfmt 6401
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
demic or epidemic product (as defined in sec-
tion 319F–3 of such Act), in addition to any 
action with respect to such drug under subpara-
graph (A) or (B), the Secretary shall notify the 
Assistant Secretary for Preparedness and Re-
sponse and the Director of the Biomedical Ad-
vanced Research and Development Authority of 
all pediatric studies in the written request 
issued
by
the
Commissioner
of
Food
and 
Drugs.’’. 
(b)
ADDITION
TO
PRIORITY
LIST
CONSIDER-
ATIONS.—Section 409I of the Public Health Service Act 
(42 U.S.C. 284m) is amended— 
(1) by striking subsection (a)(2) and inserting 
the following: 
‘‘(2) CONSIDERATION OF AVAILABLE INFORMA-
TION.—In developing and prioritizing the list under 
paragraph (1), the Secretary— 
‘‘(A) shall consider— 
‘‘(i)
therapeutic
gaps
in
pediatrics 
that may include developmental pharma-
cology, pharmacogenetic determinants of 
drug response, metabolism of drugs and 
biologics in children, and pediatric clinical 
trials; 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00082
Fmt 6652
Sfmt 6401
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(ii) particular pediatric diseases, dis-
orders or conditions where more complete 
knowledge and testing of therapeutics, in-
cluding drugs and biologics, may be bene-
ficial in pediatric populations; and 
‘‘(iii) the adequacy of necessary infra-
structure
to
conduct
pediatric
pharma-
cological research, including research net-
works and trained pediatric investigators; 
and 
‘‘(B) may consider the availability of quali-
fied countermeasures (as defined in section 
319F–1), security countermeasures (as defined 
in section 319F–2), and qualified pandemic or 
epidemic products (as defined in section 319F– 
3) to address the needs of pediatric populations, 
in consultation with the Assistant Secretary for 
Preparedness and Response, consistent with the 
purposes of this section.’’; and 
(2) in subsection (b), by striking ‘‘subsection 
(a)’’ and inserting ‘‘paragraphs (1) and (2)(A) of 
subsection (a)’’. 
(c) ADVICE AND RECOMMENDATIONS OF THE PEDI-
ATRIC ADVISORY COMMITTEE REGARDING COUNTER-
MEASURES
FOR PEDIATRIC POPULATIONS.—Subsection 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00083
Fmt 6652
Sfmt 6401
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
(b)(2) of section 14 of the Best Pharmaceuticals for Chil-
dren Act (42 U.S.C. 284m note) is amended— 
(1) in subparagraph (C), by striking the period 
and inserting ‘‘; and’’; and 
(2) by adding at the end the following: 
‘‘(D) the development of countermeasures 
(as defined in section 565(a) of the Federal 
Food, Drug, and Cosmetic Act) for pediatric 
populations.’’. 
TITLE IV—ACCELERATING MED-
ICAL COUNTERMEASURE AD-
VANCED RESEARCH AND DE-
VELOPMENT 
SEC. 401. BIOSHIELD. 
(a) PROCUREMENT
OF COUNTERMEASURES.—Sec-
tion 319F–2(c) of the Public Health Service Act (42 
U.S.C. 247d–6b(c)) is amended— 
(1) in paragraph (1)(B)(i)(III)(bb), by striking 
‘‘eight years’’ and inserting ‘‘10 years’’; 
(2) in paragraph (2)(C), by striking ‘‘the des-
ignated congressional committees (as defined in 
paragraph (10))’’ and inserting ‘‘the appropriate 
committees of Congress’’; 
(3) in paragraph (5)(B)(ii), by striking ‘‘eight 
years’’ and inserting ‘‘10 years’’; 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00084
Fmt 6652
Sfmt 6401
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
(4) in subparagraph (C) of paragraph (6)— 
(A) in the subparagraph heading, by strik-
ing
‘‘DESIGNATED
CONGRESSIONAL
COMMIT-
TEES’’ and inserting ‘‘APPROPRIATE CONGRES-
SIONAL COMMITTEES’’; and 
(B) by striking ‘‘the designated congres-
sional committees’’ and inserting ‘‘the appro-
priate congressional committees’’; and 
(5) in paragraph (7)(C)— 
(A) in clause (i)(I), by inserting ‘‘including 
advanced research and development,’’ after ‘‘as 
may reasonably be required,’’; 
(B) in clause (ii)— 
(i)
in
subclause
(III),
by
striking 
‘‘eight years’’ and inserting ‘‘10 years’’; 
and 
(ii) by striking subclause (IX) and in-
serting the following: 
‘‘(IX)
CONTRACT
TERMS.—The 
Secretary, in any contract for procure-
ment under this section— 
‘‘(aa) may specify— 
‘‘(AA) the dosing and 
administration requirements 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00085
Fmt 6652
Sfmt 6401
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
for the countermeasure to be 
developed and procured; 
‘‘(BB) the amount of 
funding that will be dedi-
cated by the Secretary for 
advanced research, develop-
ment, and procurement of 
the countermeasure; and 
‘‘(CC) the specifications 
the
countermeasure
must 
meet to qualify for procure-
ment under a contract under 
this section; and 
‘‘(bb) shall provide a clear 
statement of defined Government 
purpose limited to uses related to 
a security countermeasure, as de-
fined in paragraph (1)(B).’’; and 
(C) by adding at the end the following: 
‘‘(viii) FLEXIBILITY.—In carrying out 
this section, the Secretary may, consistent 
with the applicable provisions of this sec-
tion, enter into contracts and other agree-
ments that are in the best interest of the 
Government in meeting identified security 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00086
Fmt 6652
Sfmt 6401
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
countermeasure needs, including with re-
spect to reimbursement of the cost of ad-
vanced research and development as a rea-
sonable, allowable, and allocable direct cost 
of the contract involved.’’. 
(b) REAUTHORIZATION OF THE SPECIAL RESERVE 
FUND.—Section 319F–2 of the Public Health Service Act 
(42 U.S.C. 247d–6b) is amended— 
(1) in subsection (c)— 
(A) by striking ‘‘special reserve fund under 
paragraph (10)’’ each place it appears and in-
serting ‘‘special reserve fund as defined in sub-
section (h)’’; and 
(B) by striking paragraphs (9) and (10); 
and 
(2) by adding at the end the following: 
‘‘(g) SPECIAL RESERVE FUND.— 
‘‘(1) AUTHORIZATION OF APPROPRIATIONS.—In 
addition to amounts appropriated to the special re-
serve fund prior to the date of the enactment of this 
subsection, there is authorized to be appropriated, 
for the procurement of security countermeasures 
under subsection (c) and for carrying out section 
319L (relating to the Biomedical Advanced Research 
and Development Authority), $2,800,000,000 for the 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00087
Fmt 6652
Sfmt 6401
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
period of fiscal years 2014 through 2018. Amounts 
appropriated pursuant to the preceding sentence are 
authorized to remain available until September 30, 
2019. 
‘‘(2) USE OF SPECIAL RESERVE FUND FOR AD-
VANCED RESEARCH AND DEVELOPMENT.—The Sec-
retary may utilize not more than 50 percent of the 
amounts authorized to be appropriated under para-
graph (1) to carry out section 319L (related to the 
Biomedical Advanced Research and Development 
Authority). Amounts authorized to be appropriated 
under this subsection to carry out section 319L are 
in addition to amounts otherwise authorized to be 
appropriated to carry out such section. 
‘‘(3)
RESTRICTIONS
ON
USE
OF
FUNDS.— 
Amounts in the special reserve fund shall not be 
used to pay costs other than payments made by the 
Secretary to a vendor for advanced development 
(under section 319L) or for procurement of a secu-
rity countermeasure under subsection (c)(7). 
‘‘(4) REPORT.—Not later than 30 days after 
any date on which the Secretary determines that the 
amount of funds in the special reserve fund available 
for procurement is less than $1,500,000,000, the 
Secretary shall submit to the appropriate committees 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00088
Fmt 6652
Sfmt 6401
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
of Congress a report detailing the amount of such 
funds available for procurement and the impact such 
reduction in funding will have— 
‘‘(A)
in
meeting
the
security
counter-
measure needs identified under this section; and 
‘‘(B) on the annual Public Health Emer-
gency Medical Countermeasures Enterprise and 
Strategy Implementation Plan (pursuant to sec-
tion 2811(d)). 
‘‘(h) DEFINITIONS.—In this section: 
‘‘(1) The term ‘advanced research and develop-
ment’ has the meaning given such term in section 
319L(a). 
‘‘(2) The term ‘special reserve fund’ means the 
‘Biodefense
Countermeasures’
appropriations
ac-
count, any appropriation made available pursuant to 
section 521(a) of the Homeland Security Act of 
2002, and any appropriation made available pursu-
ant to subsection (g)(1).’’. 
SEC. 402. BIOMEDICAL ADVANCED RESEARCH AND DEVEL-
OPMENT AUTHORITY. 
(a)
DUTIES.—Section
319L(c)(4)
of
the
Public 
Health Service Act (42 U.S.C. 247d–7e(c)(4)) is amend-
ed— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00089
Fmt 6652
Sfmt 6401
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
(1)
in
subparagraph
(B)(iii),
by
inserting 
‘‘(which may include advanced research and develop-
ment for purposes of fulfilling requirements under 
the Federal Food, Drug, and Cosmetic Act or sec-
tion 351 of this Act)’’ after ‘‘development’’; and 
(2) in subparagraph (D)(iii), by striking ‘‘and 
vaccine manufacturing technologies’’ and inserting 
‘‘vaccine-manufacturing
technologies,
dose-sparing 
technologies,
efficacy-increasing
technologies,
and 
platform technologies’’. 
(b)
TRANSACTION
AUTHORITIES.—Section 
319L(c)(5) of the Public Health Service Act (42 U.S.C. 
247d–7e(c)(5)) is amended by adding at the end the fol-
lowing: 
‘‘(G) GOVERNMENT PURPOSE.—In award-
ing contracts, grants, and cooperative agree-
ments under this section, the Secretary shall 
provide a clear statement of defined Govern-
ment purpose related to activities included in 
subsection (a)(6)(B) for a qualified counter-
measure or qualified pandemic or epidemic 
product.’’. 
(c) FUND.—Paragraph (2) of section 319L(d) of the 
Public Health Service Act (42 U.S.C. 247d–7e(d)(2)) is 
amended to read as follows: 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00090
Fmt 6652
Sfmt 6401
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
‘‘(2) FUNDING.—To carry out the purposes of 
this section, there is authorized to be appropriated 
to the Fund $415,000,000 for each of fiscal years 
2013 through 2017, such amounts to remain avail-
able until expended.’’. 
(d) CONTINUED INAPPLICABILITY OF CERTAIN PRO-
VISIONS.—Section 319L(e)(1)(C) of the Public Health 
Service Act (42 U.S.C. 247d–7e(e)(1)(C)) is amended by 
striking ‘‘7 years’’ and inserting ‘‘11 years’’. 
(e) EXTENSION
OF LIMITED ANTITRUST EXEMP-
TION.— 
(1) IN GENERAL.—Section 405(b) of the Pan-
demic and All-Hazards Preparedness Act (42 U.S.C. 
247d–6a note) is amended by striking ‘‘6-year’’ and 
inserting ‘‘11-year’’. 
(2) EFFECTIVE
DATE.—This subsection shall 
take effect as if enacted on December 17, 2012. 
(f) INDEPENDENT EVALUATION.—Section 319L of 
the Public Health Service Act (42 U.S.C. 247d–7e) is 
amended by adding at the end the following: 
‘‘(f) INDEPENDENT EVALUATION.— 
‘‘(1) IN GENERAL.—Not later than 180 days 
after the date of enactment of this subsection, the 
Comptroller General of the United States shall con-
duct an independent evaluation of the activities car-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00091
Fmt 6652
Sfmt 6401
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS